Pharmaceuticals News and Research

RSS

VirtualScopics signs software licence, support agreement with IXICO

VirtualScopics, Inc., a leading provider of clinical trial imaging solutions, today announced that they have signed a multi-year software licence and support agreement with existing alliance partner, IXICO plc, the brain health company, for their proprietary imaging data and query management digital platform, TrialTracker™.

16 Dec 2014

CARLINA, Atlangram partner to develop antibiotics for osteoarticular infectious diseases

CARLINA Technologies, a biotechnology company specializing in the development of nanomedicines, today announces the signing of a partnership agreement with Atlangram for the development of innovative pharmaceutical forms of antibiotics for the targeting of osteoarticular infectious diseases.

16 Dec 2014

Joslin study could lead to improved anti-aging drugs

In a study published today by Nature, researchers at Joslin Diabetes Center used a microscopic worm (C. elegans) to identify a new path that could lead to drugs to slow aging and the chronic diseases that often accompany it--and might even lead to better cosmetics.

16 Dec 2014

Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.

16 Dec 2014

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.

16 Dec 2014

Top ten priorities for research into management of Parkinson's

Patients with Parkinson's, medics and carers have identified the top ten priorities for research into the management of the condition in a study by the University of East Anglia and Parkinson's UK.

16 Dec 2014

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

Professor Colin Garner, Chief Executive of Antibiotic Research UK (ANTRUK), the world’s first charity to tackle the impending health disaster of antibiotic resistance, welcomed the publication of the first report by the O’Neill Commission on antibiotic resistance.

14 Dec 2014

Anavex Life Sciences qualifies to trade on OTCQX

OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX, the best marketplace for established, global and growth companies.

14 Dec 2014

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial.

14 Dec 2014

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout.

14 Dec 2014

Maf1 protein that makes other proteins also controls fat levels in the body

Like a smart sensor that adjusts the lighting in each room and a home's overall temperature, a protein that governs the making of other proteins in the cell also appears capable of controlling fat levels in the body.

14 Dec 2014

Experiments to probe bacteria virulence in low gravity of space station

The University of Colorado Boulder will fly state-of-the-art hardware on the commercial SpaceX Dragon spacecraft launching to the International Space Station Dec. 19 to support experiments designed to better understand why the virulence of some pathogens increases in the low gravity of space.

14 Dec 2014

Champions reports decrease in revenue for second quarter of 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2014.

14 Dec 2014

Janssen, USAID sign MOU to fight against health threat of antibiotic-resistant bacteria

Johnson & Johnson today announced that its affiliate Janssen Therapeutics, Division of Janssen Products, LP, has signed a Memorandum of Understanding (MOU) representing the intention of the Company along with the United States Agency for International Development to step up the fight against the health threat of antibiotic-resistant bacteria.

12 Dec 2014

Abbott acquires control of Veropharm for $305 million

Abbott today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer.

12 Dec 2014

GI Partners completes acquisition of 9911 Belward Campus Drive

GI Partners today announced that it has completed the acquisition of 9911 Belward Campus Drive located in Rockville, Maryland. The acquisition was made through TechCore, LLC, which is a $1 billion discretionary core real estate fund managed by GI Partners.

11 Dec 2014

Diplomat announces new partnership with Novation through Hospital Specialty Rx Program

Diplomat, the nation's largest independent specialty pharmacy, has announced a new partnership with Novation through their Hospital Specialty Rx Program.

11 Dec 2014

OPTIMISE project to collect data that provides in-depth picture of MS experiences

Researchers will track the lives of people with multiple sclerosis (MS) in unprecedented detail in a project to improve the evaluation of treatments.

11 Dec 2014

Myriad Genetics highlights three new studies at SABCS 2014

Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.

10 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

Pharmaceuticals News and Research

VirtualScopics signs software licence, support agreement with IXICO

CARLINA, Atlangram partner to develop antibiotics for osteoarticular infectious diseases

Joslin study could lead to improved anti-aging drugs

Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Top ten priorities for research into management of Parkinson's

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

Anavex Life Sciences qualifies to trade on OTCQX

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

Maf1 protein that makes other proteins also controls fat levels in the body

Experiments to probe bacteria virulence in low gravity of space station

Champions reports decrease in revenue for second quarter of 2015

Janssen, USAID sign MOU to fight against health threat of antibiotic-resistant bacteria

Abbott acquires control of Veropharm for $305 million

GI Partners completes acquisition of 9911 Belward Campus Drive

Diplomat announces new partnership with Novation through Hospital Specialty Rx Program

OPTIMISE project to collect data that provides in-depth picture of MS experiences

Myriad Genetics highlights three new studies at SABCS 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence